Genprex

Oncology Program

Lung Cancer


Cancer

Cancer is a complex disease that can start in any site in the body when a tissue grows out of control and inhibits the body’s normal functioning. At the cell level, cancer often involves the dysregulation of multiple genes and cellular pathways, leading to the cell’s inability to maintain proper cellular functions. Re-establishing or blocking these pathways can be done through many therapeutic approaches, including gene therapy. More general information about cancer can be found at The American Cancer Society.

Lung Cancer

Genprex’s oncology program is focused on developing new treatments for cancer. Our initial therapeutic target is non-small cell lung cancer (NSCLC).  

According to the World Health Organization in 2019, lung cancer was the leading cause of cancer deaths worldwide, causing more deaths than colorectal, breast, liver or stomach cancers. In the United States, according to the American Cancer Society, it is estimated that in 2021 there will be more than 235,000 new cases of lung cancer and more than 131,000 deaths from this disease. The American Society of Clinical Oncology reports that NSCLC represents 84% of all lung cancers and has a 24% five-year survival rate. However, according to the National Cancer Institute, 57% of lung cancer diagnoses are distant, or have metastasized, and the five-year relative survival rate for Stage 4 (metastatic) NSCLC is approximately 5%. With limited benefit from current therapies, we believe there is a significant unmet medical need for new treatments for NSCLC in the United States and globally, and we believe REQORSA may be suitable for a majority of NSCLC patients.